Blank Rome partners Shannon E. McClure and Rachael G. Pontikes will serve as panelists at American Conference Institute’s (“ACI”) 2nd Annual Summit on GLP-1 Law & Policy, being held Thursday, June 4, 2026, from 7:30 a.m. to 5:00 p.m. Blank Rome is pleased to be a Supporting Sponsor of the Summit.
About the Summit
The GLP-1 market is on track to reach over $30 billion by 2030. With unebbing market demand, intellectual property (“IP”) disputes, and a microscope on advertising practices, it’s critical to stay up to date on all the legislative and litigative threats facing GLP-1 manufacturers today. Industry leaders will present sessions covering everything from advertising to mass torts to peptides.
About Their Sessions
Rachael’s session, “Push for Peptides: Post-Shortage Compounding and the Peptide Gray Market,” will take place from 9:30 to 10:15 a.m.
Description: The GLP-1 market is on track to hit $33.26 billion by 2030, and innovators and compounders alike have taken notice. Post-shortage, some GLP-1 providers are searching for new ways to meet this demand. But the cutting edge comes with uncertainty, questions, and potential pitfalls.
Panelists:
- Josh Bolin, Senior Advisor, NABP and Senior Vice President, Pulse by NABP, National Association of Boards of Pharmacy
- Jayda Greco, Partner, McDermott Will & Schulte LLP
- Rachael G. Pontikes, Partner, Blank Rome LLP
Shannon’s session, “Copyright, Trademarks, and Patents: Enforcement Efforts in Intellectual Property,” will take place from 10:30 to 11:30 a.m.
Description: Intellectual property sits at the core of investment in the research and development of novel drugs. Though patents are central to IP protection, until recently copyright and trademark disputes have dominated the GLP-1 litigation landscape. As patent litigation kicks off, and semaglutide nears the end of its patent exclusivity term, understanding the baseline of GLP-1 IP protections and threats is critical to ensuring a competitive edge in the market.
Panelists:
- Joanna T. Brougher, MPH, Esq., Owner & Principal, BioPharma Law Group, PLLC
- Ricardo Campello, Partner, Licks Attorneys
- Shannon McClure, Partner, Blank Rome LLP
Other sessions include:
- Taking Shape: The Legislative and Regulatory Landscape for GLP1s
- Building Partnerships Across the GLP-1 Industry
- Patient Health vs. Market Health in the GLP-1 Economy
- Mass Torts, Pharmacovigilance, and Litigation Readiness
- Going Viral: The Regulations, Restrictions, and Reputational Dangers of GLP-1 Advertising
- Prognostication Station: Anticipating the Long Tail of the GLP-1 Market
For more information and to register, please visit the event webpage.